Quadrant Capital Group’s Aerie Pharmaceuticals AERI Stock Holding History

Quadrant Capital Group’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-600	Closed	-$9K	–	2900
2022 Q3	$9K	Buy	600 +506	+538%	+$5.88K	﹤0.01%	1946
2022 Q2	$1K	Sell	94 -64	-41%	-$451	﹤0.01%	2499
2022 Q1	$1K	Buy	+158	New	+$1.22K	﹤0.01%	2457
2020 Q2	–	Sell	-106	Closed	-$1K	–	2461
2020 Q1	$1K	Hold	106	–	–	﹤0.01%	2074
2019 Q4	$2K	Hold	106	–	–	﹤0.01%	2278
2019 Q3	$2K	Buy	+106	New	+$2.43K	﹤0.01%	2142

Quadrant Capital Group's AERI Position: Q4 2022 in Review

Quadrant Capital Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 600 shares — an estimated $9K sold.

Quadrant Capital Group first reported a position in AERI in Q3 2019 and held it in 6 quarters. The position peaked at $9K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Quadrant Capital Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Quadrant Capital Group sold 600 Aerie Pharmaceuticals shares in Q4 2022, an estimated $9K.
Quadrant Capital Group first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 6 quarters.
Quadrant Capital Group's Aerie Pharmaceuticals position peaked at $9K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.